Canaccord Genuity analyst Aravinda Galappatthige downgrades Cogeco Communications (TSX:CCA) from Buy to Hold.
Leap Therapeutics To Present Updated Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Preclinical Data In Colorectal Cancer Models At The Society of Immunotherapy for Cancer Annual Meeting
CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be
